{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T10:46:07Z","timestamp":1783334767112,"version":"3.54.6"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2014,6,26]],"date-time":"2014-06-26T00:00:00Z","timestamp":1403740800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Osteoporos Rep"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1007\/s11914-014-0225-0","type":"journal-article","created":{"date-parts":[[2014,6,25]],"date-time":"2014-06-25T03:24:01Z","timestamp":1403666641000},"page":"279-288","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":58,"title":["Osteogenesis Imperfecta: Diagnosis and Treatment"],"prefix":"10.1007","volume":"12","author":[{"given":"A.","family":"Biggin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. F.","family":"Munns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,6,26]]},"reference":[{"issue":"2","key":"225_CR1","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1136\/jmg.16.2.101","volume":"16","author":"DO Sillence","year":"1979","unstructured":"Sillence DO, Senn A, Danks DM. Genetic heterogeneity in osteogenesis imperfecta. J Med Genet. 1979;16(2):101\u201316.","journal-title":"J Med Genet"},{"issue":"9","key":"225_CR2","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/nrendo.2011.81","volume":"7","author":"A Forlino","year":"2011","unstructured":"Forlino A, Cabral WA, Barnes AM, Marini JC. New perspectives on osteogenesis imperfecta. Nat Rev Endocrinol. 2011;7(9):540\u201357.","journal-title":"Nat Rev Endocrinol"},{"issue":"2","key":"225_CR3","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.ajhg.2012.06.005","volume":"91","author":"TJ Cho","year":"2012","unstructured":"Cho TJ, Lee KE, Lee SK, Song SJ, Kim KJ, Jeon D, et al. A single recurrent mutation in the 5\u2032-UTR of IFITM5 causes osteogenesis imperfecta type V. Am J Hum Genet. 2012;91(2):343\u20138. Reports a novel gene responsible for an OI phenotype.","journal-title":"Am J Hum Genet"},{"issue":"8","key":"225_CR4","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1359\/jbmr.070418","volume":"22","author":"MS Cheung","year":"2007","unstructured":"Cheung MS, Glorieux FH, Rauch F. Natural history of hyperplastic callus formation in osteogenesis imperfecta type V. J Bone Miner Res. 2007;22(8):1181\u20136.","journal-title":"J Bone Miner Res"},{"issue":"1","key":"225_CR5","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1359\/jbmr.2002.17.1.30","volume":"17","author":"FH Glorieux","year":"2002","unstructured":"Glorieux FH, Ward LM, Rauch F, Lalic L, Roughley PJ, Travers R. Osteogenesis imperfecta type VI: a form of brittle bone disease with a mineralization defect. J Bone Miner Res. 2002;17(1):30\u20138.","journal-title":"J Bone Miner Res"},{"issue":"3","key":"225_CR6","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.ajhg.2011.01.015","volume":"88","author":"J Becker","year":"2011","unstructured":"Becker J, Semler O, Gilissen C, Li Y, Bolz HJ, Giunta C, et al. Exome sequencing identifies truncating mutations in human SERPINF1 in autosomal-recessive osteogenesis imperfecta. Am J Hum Genet. 2011;88(3):362\u201371. Reports a novel gene responsible for an OI phenotype.","journal-title":"Am J Hum Genet"},{"issue":"3","key":"225_CR7","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.bone.2006.10.010","volume":"40","author":"C Land","year":"2007","unstructured":"Land C, Rauch F, Travers R, Glorieux FH. Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment. Bone. 2007;40(3):638\u201344.","journal-title":"Bone"},{"issue":"1","key":"225_CR8","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S8756-3282(02)00790-1","volume":"31","author":"LM Ward","year":"2002","unstructured":"Ward LM, Rauch F, Travers R, Chabot G, Azouz EM, Lalic L, et al. Osteogenesis imperfecta type VII: an autosomal recessive form of brittle bone disease. Bone. 2002;31(1):12\u20138.","journal-title":"Bone"},{"issue":"2","key":"225_CR9","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.cell.2006.08.039","volume":"127","author":"R Morello","year":"2006","unstructured":"Morello R, Bertin TK, Chen Y, Hicks J, Tonachini L, Monticone M, et al. CRTAP is required for prolyl 3- hydroxylation and mutations cause recessive osteogenesis imperfecta. Cell. 2006;127(2):291\u2013304.","journal-title":"Cell"},{"issue":"4","key":"225_CR10","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1136\/jmg.2008.062729","volume":"46","author":"A Willaert","year":"2009","unstructured":"Willaert A, Malfait F, Symoens S, Gevaert K, Kayserili H, Megarbane A, et al. Recessive osteogenesis imperfecta caused by LEPRE1 mutations: clinical documentation and identification of the splice form responsible for prolyl 3-hydroxylation. J Med Genet. 2009;46(4):233\u201341. Reports a novel gene responsible for an OI phenotype.","journal-title":"J Med Genet"},{"issue":"4","key":"225_CR11","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.ajhg.2009.09.001","volume":"85","author":"FS Dijk van","year":"2009","unstructured":"van Dijk FS, Nesbitt IM, Zwikstra EH, Nikkels PG, Piersma SR, Fratantoni SA, et al. PPIB mutations cause severe osteogenesis imperfecta. Am J Hum Genet. 2009;85(4):521\u20137. Reports a novel gene responsible for an OI phenotype.","journal-title":"Am J Hum Genet"},{"issue":"3","key":"225_CR12","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.ajhg.2010.01.034","volume":"86","author":"HE Christiansen","year":"2010","unstructured":"Christiansen HE, Schwarze U, Pyott SM, AlSwaid A, Al Balwi M, Alrasheed S, et al. Homozygosity for a missense mutation in SERPINH1, which encodes the collagen chaperone protein HSP47, results in severe recessive osteogenesis imperfecta. Am J Hum Genet. 2010;86(3):389\u201398. Reports a novel gene responsible for an OI phenotype.","journal-title":"Am J Hum Genet"},{"issue":"1","key":"225_CR13","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ajhg.2010.05.016","volume":"87","author":"P Lapunzina","year":"2010","unstructured":"Lapunzina P, Aglan M, Temtamy S, Caparros-Martin JA, Valencia M, Leton R, et al. Identification of a frameshift mutation in Osterix in a patient with recessive osteogenesis imperfecta. Am J Hum Genet. 2010;87(1):110\u20134. Reports a novel gene responsible for an OI phenotype.","journal-title":"Am J Hum Genet"},{"issue":"5","key":"225_CR14","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1136\/jmedgenet-2013-101567","volume":"50","author":"S Fahiminiya","year":"2013","unstructured":"Fahiminiya S, Majewski J, Mort J, Moffatt P, Glorieux FH, Rauch F. Mutations in WNT1 are a cause of osteogenesis imperfecta. J Med Genet. 2013;50(5):345\u20138. Reports a novel gene responsible for an OI phenotype.","journal-title":"J Med Genet"},{"key":"225_CR15","doi-asserted-by":"crossref","unstructured":"Fahiminiya S, Majewski J, Al-Jallad H, Moffatt P, Mort J, Glorieux FH, et al. Osteoporosis caused by mutations in PLS3\u2014clinical and bone tissue characteristics. J Bone Miner Res. 2014. doi: 10.1002\/jbmr.2208 Reports a novel gene responsible for an OI phenotype.","DOI":"10.1002\/jbmr.2208"},{"issue":"2","key":"225_CR16","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/humu.21647","volume":"33","author":"V Martinez-Glez","year":"2012","unstructured":"Martinez-Glez V, Valencia M, Caparros-Martin JA, Aglan M, Temtamy S, Tenorio J, et al. Identification of a mutation causing deficient BMP1\/mTLD proteolytic activity in autosomal recessive osteogenesis imperfecta. Hum Mutat. 2012;33(2):343\u201350. Reports a novel gene responsible for an OI phenotype.","journal-title":"Hum Mutat"},{"issue":"2","key":"225_CR17","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/ajmg.a.30231","volume":"131","author":"R Ha-Vinh","year":"2004","unstructured":"Ha-Vinh R, Alanay Y, Bank RA, Campos-Xavier AB, Zankl A, Superti-Furga A, et al. Phenotypic and molecular characterization of Bruck syndrome (osteogenesis imperfecta with contractures of the large joints) caused by a recessive mutation in PLOD2. Am J Med Genet A. 2004;131(2):115\u201320.","journal-title":"Am J Med Genet A"},{"issue":"4","key":"225_CR18","first-page":"582","volume":"34","author":"M Volodarsky","year":"2013","unstructured":"Volodarsky M, Markus B, Cohen I, Staretz-Chacham O, Flusser H, Landau D, et al. A deletion mutation in TMEM38B associated with autosomal recessive osteogenesis imperfecta. Hum Mutat. 2013;34(4):582\u20136. Reports a novel gene responsible for an OI phenotype.","journal-title":"Hum Mutat"},{"issue":"3","key":"225_CR19","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1002\/jbmr.250","volume":"26","author":"BP Kelley","year":"2011","unstructured":"Kelley BP, Malfait F, Bonafe L, Baldridge D, Homan E, Symoens S, et al. Mutations in FKBP10 cause recessive osteogenesis imperfecta and Bruck syndrome. J Bone Miner Res. 2011;26(3):666\u201372. Reports a novel gene responsible for an OI phenotype.","journal-title":"J Bone Miner Res"},{"issue":"5","key":"225_CR20","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/ajmg.a.33909","volume":"155A","author":"ML Warman","year":"2011","unstructured":"Warman ML, Cormier-Daire V, Hall C, Krakow D, Lachman R, LeMerrer M, et al. Nosology and classification of genetic skeletal disorders: 2010 revision. Am J Med Genet A. 2011;155A(5):943\u201368.","journal-title":"Am J Med Genet A"},{"issue":"4","key":"225_CR21","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3109\/03008209509010818","volume":"31","author":"PH Byers","year":"1995","unstructured":"Byers PH. Etiology of osteogenesis imperfecta: an overview of biochemical and molecular genetic analyses. Connect Tissue Res. 1995;31(4):257\u20139.","journal-title":"Connect Tissue Res"},{"issue":"10","key":"225_CR22","first-page":"36545","volume":"8","author":"FS Dijk Van","year":"2014","unstructured":"Van Dijk FS, Sillence DO. Osteogenesis imperfecta: clinical diagnosis, nomenclature and severity assessment. Am J Med Genet A. 2014;8(10):36545.","journal-title":"Am J Med Genet A"},{"key":"225_CR23","doi-asserted-by":"crossref","first-page":"540178","DOI":"10.4061\/2011\/540178","volume":"2011","author":"IM Ben Amor","year":"2011","unstructured":"Ben Amor IM, Glorieux FH, Rauch F. Genotype-phenotype correlations in autosomal dominant osteogenesis imperfecta. J Osteoporos. 2011;2011:540178.","journal-title":"J Osteoporos"},{"issue":"1","key":"225_CR24","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1172\/JCI119519","volume":"100","author":"K Misof","year":"1997","unstructured":"Misof K, Landis WJ, Klaushofer K, Fratzl P. Collagen from the osteogenesis imperfecta mouse model (oim) shows reduced resistance against tensile stress. J Clin Invest. 1997;100(1):40\u20135.","journal-title":"J Clin Invest"},{"issue":"6","key":"225_CR25","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S8756-3282(00)00269-6","volume":"26","author":"F Rauch","year":"2000","unstructured":"Rauch F, Travers R, Parfitt AM, Glorieux FH. Static and dynamic bone histomorphometry in children with osteogenesis imperfecta. Bone. 2000;26(6):581\u20139.","journal-title":"Bone"},{"issue":"7679","key":"225_CR26","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/S0140-6736(70)92070-2","volume":"2","author":"RGG Russell","year":"1970","unstructured":"Russell RGG, Bisaz S, Fleisch H, Currey HL, Rubinstein HM, Dietz AA, et al. Inorganic pyrophosphate in plasma, urine, and synovial fluid of patients with pyrophosphate arthropathy (chondrocalcinosis or pseudogout). Lancet. 1970;2(7679):899\u2013902.","journal-title":"Lancet"},{"issue":"12 Suppl","key":"225_CR27","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1002\/1097-0142(20000615)88:12+<2961::AID-CNCR12>3.0.CO;2-L","volume":"88","author":"MJ Rogers","year":"2000","unstructured":"Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J, et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer. 2000;88(12 Suppl):2961\u201378.","journal-title":"Cancer"},{"issue":"4","key":"225_CR28","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1359\/jbmr.1998.13.4.581","volume":"13","author":"SP Luckman","year":"1998","unstructured":"Luckman SP, Hughes DE, Coxon FP, Russell RGG, Rogers MJ. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res. 1998;13(4):581\u20139.","journal-title":"J Bone Miner Res"},{"issue":"5","key":"225_CR29","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1002\/jbmr.5650090521","volume":"9","author":"JR Green","year":"1994","unstructured":"Green JR, Muller K, Jaeggi KA. Preclinical pharmacology of CGP 42\u2032446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res. 1994;9(5):745\u201351.","journal-title":"J Bone Miner Res"},{"issue":"11","key":"225_CR30","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1177\/009127002762491316","volume":"42","author":"T Chen","year":"2002","unstructured":"Chen T, Berenson J, Vescio R, Swift R, Gilchick A, Goodin S, et al. Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharmacol. 2002;42(11):1228\u201336.","journal-title":"J Clin Pharmacol"},{"key":"225_CR31","volume":"4","author":"CA Phillipi","year":"2008","unstructured":"Phillipi CA, Remmington T, Steiner RD. Bisphosphonate therapy for osteogenesis imperfecta. Cochrane Database Syst Rev. 2008;4, CD005088.","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"225_CR32","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.3109\/03008209509116827","volume":"31","author":"DO Sillence","year":"1995","unstructured":"Sillence DO, Morley K, Ault JE. Clinical management of osteogenesis imperfecta. Connect Tissue Res. 1995;31(4):S15\u201321.","journal-title":"Connect Tissue Res"},{"issue":"5","key":"225_CR33","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1007\/BF00350961","volume":"16","author":"JP Devogelaer","year":"1987","unstructured":"Devogelaer JP, Malghem J, Maldague B, Nagant de Deuxchaisnes C. Radiological manifestations of bisphosphonate treatment with APD in a child suffering from osteogenesis imperfecta. Skeletal Radiol. 1987;16(5):360\u20133.","journal-title":"Skeletal Radiol"},{"issue":"14","key":"225_CR34","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJM199810013391402","volume":"339","author":"FH Glorieux","year":"1998","unstructured":"Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med. 1998;339(14):947\u201352.","journal-title":"N Engl J Med"},{"issue":"1","key":"225_CR35","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/j.1651-2227.1998.tb01388.x","volume":"87","author":"E Astrom","year":"1998","unstructured":"Astrom E, Soderhall S. Beneficial effect of bisphosphonate during five years of treatment of severe osteogenesis imperfecta. Acta Paediatr. 1998;87(1):64\u20138.","journal-title":"Acta Paediatr"},{"issue":"5","key":"225_CR36","first-page":"1846","volume":"85","author":"H Plotkin","year":"2000","unstructured":"Plotkin H, Rauch F, Bishop NJ, Montpetit K, Ruck-Gibis J, Travers R, et al. Pamidronate treatment of severe osteogenesis imperfecta in children under 3\u00a0years of age. J Clin Endocrinol Metab. 2000;85(5):1846\u201350.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"225_CR37","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1159\/000351374","volume":"79","author":"MB Alcausin","year":"2013","unstructured":"Alcausin MB, Briody J, Pacey V, Ault J, McQuade M, Bridge C, et al. Intravenous pamidronate treatment in children with moderate-to-severe osteogenesis imperfecta started under three years of age. Horm Res Paediatr. 2013;79(6):333\u201340. Reported that cyclic IV pamidronate started under 3\u00a0years of age improved bone density, reduced fracture frequency and resulted in attainment of motor milestones at an earlier age.","journal-title":"Horm Res Paediatr"},{"issue":"9","key":"225_CR38","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1172\/JCI0215952","volume":"110","author":"F Rauch","year":"2002","unstructured":"Rauch F, Travers R, Plotkin H, Glorieux FH. The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta. J Clin Invest. 2002;110(9):1293\u20139.","journal-title":"J Clin Invest"},{"issue":"2","key":"225_CR39","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00223-001-1055-5","volume":"72","author":"JR Shapiro","year":"2003","unstructured":"Shapiro JR, McCarthy EF, Rossiter K, Ernest K, Gelman R, Fedarko N, et al. The effect of intravenous pamidronate on bone mineral density, bone histomorphometry, and parameters of bone turnover in adults with type IA osteogenesis imperfecta. Calcif Tissue Int. 2003;72(2):103\u201312.","journal-title":"Calcif Tissue Int"},{"issue":"5\u20136","key":"225_CR40","first-page":"485","volume":"25","author":"ER Barros","year":"2012","unstructured":"Barros ER, Saraiva GL, de Oliveira TP, Lazaretti-Castro M. Safety and efficacy of a 1-year treatment with zoledronic acid compared with pamidronate in children with osteogenesis imperfecta. J Pediatr Endocrinol Metab. 2012;25(5\u20136):485\u201391.","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"9419","key":"225_CR41","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0140-6736(04)16101-1","volume":"363","author":"R Sakkers","year":"2004","unstructured":"Sakkers R, Kok D, Engelbert R, van Dongen A, Jansen M, Pruijs H, et al. Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study. Lancet. 2004;363(9419):1427\u201331.","journal-title":"Lancet"},{"issue":"7","key":"225_CR42","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1359\/jbmr.090213","volume":"24","author":"F Rauch","year":"2009","unstructured":"Rauch F, Munns CF, Land C, Cheung M, Glorieux FH. Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo-controlled study. J Bone Miner Res. 2009;24(7):1282\u20139.","journal-title":"J Bone Miner Res"},{"issue":"2","key":"225_CR43","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1210\/jc.2010-0636","volume":"96","author":"LM Ward","year":"2011","unstructured":"Ward LM, Rauch F, Whyte MP, D\u2019Astous J, Gates PE, Grogan D, et al. Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled study. J Clin Endocrinol Metab. 2011;96(2):355\u201364.","journal-title":"J Clin Endocrinol Metab"},{"key":"225_CR44","doi-asserted-by":"crossref","unstructured":"Bishop N, Adami S, Ahmed SF, Ant\u00dbn J, Arundel P, Burren CP, et al. Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial. Lancet. 2013. doi: 10.1016\/S0140-6736(13)61091-0 Reported that oral risedronate increased areal BMD and reduced risk of first and recurrent clinical fractures in children with OI.","DOI":"10.1016\/S0140-6736(13)61091-0"},{"issue":"4","key":"225_CR45","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.bone.2006.11.020","volume":"40","author":"F Rauch","year":"2007","unstructured":"Rauch F, Cornibert S, Cheung M, Glorieux FH. Long-bone changes after pamidronate discontinuation in children and adolescents with osteogenesis imperfecta. Bone. 2007;40(4):821\u20137.","journal-title":"Bone"},{"key":"225_CR46","first-page":"OP13","volume":"2","author":"A Biggin","year":"2013","unstructured":"Biggin A, Zheng L, Briody J, McQuade M, Munns CF. Long-term effects of bisphosphonate therapy in children with osteogenesis imperfecta. Bone. 2013;2:OP13. Abstracts.","journal-title":"Bone"},{"issue":"6","key":"225_CR47","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1093\/annonc\/mdj105","volume":"17","author":"T Tanvetyanon","year":"2006","unstructured":"Tanvetyanon T, Stiff PJ. Management of the adverse effects associated with intravenous bisphosphonates. Ann Oncol. 2006;17(6):897\u2013907.","journal-title":"Ann Oncol"},{"issue":"2","key":"225_CR48","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1210\/jc.2008-1531","volume":"94","author":"LK Bachrach","year":"2009","unstructured":"Bachrach LK, Ward LM. Clinical review 1: bisphosphonate use in childhood osteoporosis. J Clin Endocrinol Metab. 2009;94(2):400\u20139.","journal-title":"J Clin Endocrinol Metab"},{"key":"225_CR49","doi-asserted-by":"crossref","unstructured":"Rossini M, Adami S, Viapiana O, Ortolani R, Vella A, Fracassi E, et al. Circulating gammadelta T cells and the risk of acute-phase response after zoledronic acid administration. J Bone Min Res. 2012;27(1):227\u201330.","DOI":"10.1002\/jbmr.521"},{"issue":"2","key":"225_CR50","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1592\/phco.24.2.195.33143","volume":"24","author":"RE Robinson","year":"2004","unstructured":"Robinson RE, Nahata MC, Hayes JR, Batisky DL, Bates CM, Mahan JD. Effectiveness of pretreatment in decreasing adverse events associated with pamidronate in children and adolescents. Pharmacotherapy. 2004;24(2):195\u20137.","journal-title":"Pharmacotherapy"},{"issue":"3","key":"225_CR51","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1210\/jc.2002-021371","volume":"88","author":"F Rauch","year":"2003","unstructured":"Rauch F, Plotkin H, Travers R, Zeitlin L, Glorieux FH. Osteogenesis imperfecta types I, III, and IV: effect of pamidronate therapy on bone and mineral metabolism. J Clin Endocrinol Metab. 2003;88(3):986\u201392.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"225_CR52","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.bone.2004.03.008","volume":"35","author":"CF Munns","year":"2004","unstructured":"Munns CF, Rauch F, Mier RJ, Glorieux FH. Respiratory distress with pamidronate treatment in infants with severe osteogenesis imperfecta. Bone. 2004;35(1):231\u20134.","journal-title":"Bone"},{"issue":"5 Pt 1","key":"225_CR53","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1542\/peds.111.5.1030","volume":"111","author":"L Zeitlin","year":"2003","unstructured":"Zeitlin L, Rauch F, Plotkin H, Glorieux FH. Height and weight development during four years of therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types I, III, and IV. Pediatrics. 2003;111(5 Pt 1):1030\u20136.","journal-title":"Pediatrics"},{"issue":"5","key":"225_CR54","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1056\/NEJMoa023110","volume":"349","author":"MP Whyte","year":"2003","unstructured":"Whyte MP, Wenkert D, Clements KL, McAlister WH, Mumm S. Bisphosphonate-induced osteopetrosis. N Engl J Med. 2003;349(5):457\u201363.","journal-title":"N Engl J Med"},{"issue":"3","key":"225_CR55","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1159\/000355111","volume":"81","author":"A Biggin","year":"2014","unstructured":"Biggin A, Briody JN, Ormshaw E, Wong KK, Bennetts BH, Munns CF. Fracture during intravenous bisphosphonate treatment in a child with osteogenesis imperfecta: an argument for a more frequent, low-dose treatment regimen. Horm Res Paediatr. 2014;81(3):204\u201310.","journal-title":"Horm Res Paediatr"},{"issue":"11","key":"225_CR56","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1359\/JBMR.040814","volume":"19","author":"CF Munns","year":"2004","unstructured":"Munns CF, Rauch F, Zeitlin L, Fassier F, Glorieux FH. Delayed osteotomy but not fracture healing in pediatric osteogenesis imperfecta patients receiving pamidronate. J Bone Miner Res. 2004;19(11):1779\u201386.","journal-title":"J Bone Miner Res"},{"issue":"5","key":"225_CR57","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jpeds.2008.05.003","volume":"153","author":"C Chahine","year":"2008","unstructured":"Chahine C, Cheung MS, Head TW, Schwartz S, Glorieux RH, Rauch F. Tooth extraction socket healing in paediatric patients treated with intravenous pamidronate. J Pediatr. 2008;153(5):719\u201320.","journal-title":"J Pediatr"},{"issue":"1","key":"225_CR58","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/adj.12140","volume":"59","author":"RN Bhatt","year":"2014","unstructured":"Bhatt RN, Hibbert SA, Munns CF. The use of bisphosphonates in children: review of the literature and guidelines for dental management. Aust Dent J. 2014;59(1):9\u201319. Reports the pediatric uses and adverse effects of bisphosphonates and provides recommendations on the dental management of children receiving bisphosphonates.","journal-title":"Aust Dent J"},{"issue":"1","key":"225_CR59","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.bone.2011.01.003","volume":"49","author":"M Pazianas","year":"2011","unstructured":"Pazianas M, Abrahamsen B. Safety of bisphosphonates. Bone. 2011;49(1):103\u201310.","journal-title":"Bone"},{"issue":"10","key":"225_CR60","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1359\/JBMR.040711","volume":"19","author":"CF Munns","year":"2004","unstructured":"Munns CF, Rauch F, Ward L, Glorieux FH. Maternal and fetal outcome after long-term pamidronate treatment before conception: a report of two cases. J Bone Miner Res. 2004;19(10):1742\u20135.","journal-title":"J Bone Miner Res"},{"issue":"12","key":"225_CR61","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/S1701-2163(16)34026-9","volume":"30","author":"N Djokanovic","year":"2008","unstructured":"Djokanovic N, Klieger-Grossmann C, Koren G. Does treatment with bisphosphonates endanger the human pregnancy? J Obstetrics Gynaecol Can. 2008;30(12):1146\u20138.","journal-title":"J Obstetrics Gynaecol Can"},{"issue":"4","key":"225_CR62","first-page":"386","volume":"74","author":"H Binder","year":"1993","unstructured":"Binder H, Conway A, Gerber LH. Rehabilitation approaches to children with osteogenesis imperfecta: a ten-year experience. Arch Phys Med Rehabil. 1993;74(4):386\u201390.","journal-title":"Arch Phys Med Rehabil"},{"key":"225_CR63","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/00003086-198109000-00015","volume":"159","author":"EE Bleck","year":"1981","unstructured":"Bleck EE. Nonoperative treatment of osteogenesis imperfecta: orthotic and mobility management. Clin Orthop Relat Res. 1981;159:111\u201322.","journal-title":"Clin Orthop Relat Res"},{"issue":"5","key":"225_CR64","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.apmr.2003.08.085","volume":"85","author":"RH Engelbert","year":"2004","unstructured":"Engelbert RH, Uiterwaal CS, Gerver WJ, van der Net JJ, Pruijs HE, Helders PJ. Osteogenesis imperfecta in childhood: impairment and disability. A prospective study with 4-year follow-up. Arch Phys Med Rehabil. 2004;85(5):772\u20138.","journal-title":"Arch Phys Med Rehabil"},{"issue":"1","key":"225_CR65","first-page":"77","volume":"7","author":"O Semler","year":"2007","unstructured":"Semler O, Fricke O, Vezyroglou K, Stark C, Schoenau E. Preliminary results on the mobility after whole body vibration in immobilized children and adolescents. J Musculoskelet Nueronal Interact. 2007;7(1):77\u201381.","journal-title":"J Musculoskelet Nueronal Interact"},{"issue":"3","key":"225_CR66","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s11832-011-0341-7","volume":"5","author":"J Ruck","year":"2011","unstructured":"Ruck J, Dahan-Oliel N, Montpetit K, Rauch F, Fassier F. Fassier-Duval femoral rodding in children with osteogenesis imperfecta receiving bisphosphonates: functional outcomes at one year. J Child Orthop. 2011;5(3):217\u201324.","journal-title":"J Child Orthop"},{"issue":"4","key":"225_CR67","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1097\/BPO.0b013e31821bfb50","volume":"31","author":"O Birke","year":"2011","unstructured":"Birke O, Davies N, Latimer M, Little DG, Bellemore M. Experience with the Fassier-Duval telescopic rod: first 24 consecutive cases with a minimum of 1-year follow-up. J Pediatr Orthop. 2011;31(4):458\u201364.","journal-title":"J Pediatr Orthop"},{"issue":"1","key":"225_CR68","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/MOP.0b013e3282f35f03","volume":"20","author":"P Esposito","year":"2008","unstructured":"Esposito P, Plotkin H. Surgical treatment of osteogenesis imperfecta: current concepts. Curr Opin Pediatr. 2008;20(1):52\u20137.","journal-title":"Curr Opin Pediatr"},{"issue":"6","key":"225_CR69","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1007\/s005860000165","volume":"9","author":"GJ Janus","year":"2000","unstructured":"Janus GJ, Finidori G, Engelbert RH, Pouliquen M, Pruijs JE. Operative treatment of severe scoliosis in osteogenesis imperfecta: results of 20 patients after halo traction and posterior spondylodesis with instrumentation. Eur Spine J. 2000;9(6):486\u201391.","journal-title":"Eur Spine J"},{"issue":"6","key":"225_CR70","doi-asserted-by":"crossref","first-page":"950","DOI":"10.3171\/jns.1997.86.6.0950","volume":"86","author":"PD Sawin","year":"1997","unstructured":"Sawin PD, Menezes AH. Basilar invagination in osteogenesis imperfecta and related osteochondrodysplasias: medical and surgical management. J Neurosurg. 1997;86(6):950\u201360.","journal-title":"J Neurosurg"},{"key":"225_CR71","unstructured":"Chiasson RM, Munns C, Zeitlin L. Interdisciplinary treatment approach for children with osteogenesis imperfecta: Shriners Hospitals for Children; 2004."},{"issue":"3","key":"225_CR72","first-page":"183","volume":"12","author":"O Semler","year":"2012","unstructured":"Semler O, Netzer C, Hoyer-Kuhn H, Becker J, Eysel P, Schoenau E. First use of the RANKL antibody denosumab in Osteogenesis Imperfecta Type VI. J Musculoskelet Nueronal Interact. 2012;12(3):183\u20138. Reported that denosumab was well tolerated and reversibly reduced bone resorption in children with OI type VI. Denosumab may be a new treatment option for patients with OI Type VI.","journal-title":"J Musculoskelet Nueronal Interact"},{"issue":"1","key":"225_CR73","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/jbmr.1717","volume":"28","author":"BP Sinder","year":"2013","unstructured":"Sinder BP, Eddy MM, Ominsky MS, Caird MS, Marini JC, Kozloff KM. Sclerostin antibody improves skeletal parameters in a Brtl\/+mouse model of osteogenesis imperfecta. JBMR. 2013;28(1):73\u201380.","journal-title":"JBMR"},{"issue":"6","key":"225_CR74","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.molmed.2005.04.006","volume":"11","author":"S Millington-Ward","year":"2005","unstructured":"Millington-Ward S, McMahon HP, Farrar GJ. Emerging therapeutic approaches for osteogenesis imperfecta. Trends Mol Med. 2005;11(6):299\u2013305.","journal-title":"Trends Mol Med"}],"container-title":["Current Osteoporosis Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11914-014-0225-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11914-014-0225-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11914-014-0225-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,9]],"date-time":"2022-04-09T06:27:57Z","timestamp":1649485677000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11914-014-0225-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6,26]]},"references-count":74,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["225"],"URL":"https:\/\/doi.org\/10.1007\/s11914-014-0225-0","relation":{},"ISSN":["1544-1873","1544-2241"],"issn-type":[{"value":"1544-1873","type":"print"},{"value":"1544-2241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,26]]}}}